ArticleMolecular cancer2023

A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better.

Dijana Djureinovic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.